Lung cancer vaccine

Drug Profile

Lung cancer vaccine

Latest Information Update: 17 Aug 2007

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Lung cancer

Most Recent Events

  • 02 Feb 2000 A clinical study has been added to the adverse events section and the Cancer therapeutic trials section
  • 16 May 1998 Investigation in Lung cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top